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The interferon-related developmental regulator 1
is used by human papillomavirus to suppress NFkB
activation
Bart Tummers1, Renske Goedemans1, Laetitia P.L. Pelascini2, Ekaterina S. Jordanova3, Edith M.G. van Esch4,
Craig Meyers5, Cornelis J.M. Melief6, Judith M. Boer7,w & Sjoerd H. van der Burg1
High-risk human papillomaviruses (hrHPVs) infect keratinocytes and successfully evade host
immunity despite the fact that keratinocytes are well equipped to respond to innate and
adaptive immune signals. Using non-infected and freshly established or persistent hrHPV-
infected keratinocytes we show that hrHPV impairs the acetylation of NFkB/RelA K310 in
keratinocytes. As a consequence, keratinocytes display a decreased pro-inﬂammatory
cytokine production and immune cell attraction in response to stimuli of the innate or
adaptive immune pathways. HPV accomplishes this by augmenting the expression of
interferon-related developmental regulator 1 (IFRD1) in an EGFR-dependent manner.
Restoration of NFkB/RelA acetylation by IFRD1 shRNA, cetuximab treatment or the HDAC1/3
inhibitor entinostat increases basal and induced cytokine expression. Similar observations
are made in IFRD1-overexpressing HPV-induced cancer cells. Thus, our study reveals an
EGFR–IFRD1-mediated viral immune evasion mechanism, which can also be exploited by
cancer cells.
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H
igh-risk human papillomaviruses (hrHPVs) are absolutely
species-speciﬁc small double-stranded DNA viruses that
primarily target undifferentiated keratinocytes (KCs) of
squamous epithelia via micro-wounds and abrasions. HrHPV
infections can last up to 2 years despite viral activity in infected
KCs, the expression of viral antigens and the presence of
KC-expressed pattern recognition receptors (PRRs)1–4 that
should lead to activation of innate and adaptive immune
responses. This indicates that hrHPV has evolved mechanisms
to transiently evade innate and adaptive immune mechanisms.
Ultimately, the majority of hrHPV infections are controlled by
the immune system, in particular by type-1 interferon (IFN)-g
and tumour necrosis factor (TNF)-a cytokine-producing
T cells5. In case of immune failure, hrHPV causes cancer of the
anogenital and/or head and neck regions6.
Upon infection, hrHPV alters the immune-related response of
KCs to various innate and adaptive immune stimuli, resulting in
impaired expression of IFN-stimulated genes, interferon regula-
tory transcription factor-induced genes and NFkB-induced
genes3,7–12, suggesting that HPV hampers STAT1 and NFkB
activation. HPV-infected KCs display downregulated basal
expression of STAT1 and lowered STAT1 protein levels, explain-
ing the impaired expression of IFN-stimulated genes13–16.
Furthermore, soon after infection HPV upregulates the cellular
deubiquitinase ubiquitin carboxy-terminal hydrolase L1
(UCHL1) to impair PRR-induced NFkB activation by upstream
interference with TRAF3, TRAF6 and NEMO8. The upregulation
of UCHL1, however, cannot explain how the virus manages to
suppress the KCs response to adaptive immune signals12. In
addition, repressing UCHL1 does not fully restore NFkB
signalling via PRR8, suggesting that one or more additional
mechanisms are in play to suppress NFkB signalling.
In this study, we analyse NFkB activation and subsequent
cytokine/chemokine production following IFN-g and TNF-a
stimulation in uninfected and HPV-infected primary KCs. Our
study reveals that RelA acetylation, needed for NFkB transcrip-
tional activity17, is impaired in hrHPV-infected KCs. The HPV-
induced overexpression of the cellular protein interferon-related
developmental regulator 1 (IFRD1) is shown to be instrumental
in this process and involves histone deacetylases (HDACs) 1
and/or 3. The augmented expression of IFRD1 is the result of
the HPV-mediated upregulation of the epidermal growth
factor receptor (EGFR). Blocking of IFRD1 protein expression
by small hairpin RNA (shRNA) or via the anti-EGFR antibody
cetuximab restores NFkB/RelA-mediated cytokine expression.
Additional data suggest that IFRD1 may have a similar role in
suppressing cytokine/chemokine production in HPV-positive
cervical cancer cells.
Results
HrHPV impairs the KCs cytokine response to IFN-c and TNF-a.
To evaluate whether the KCs immune response following the
exposure to IFN-g and/or TNF-a is attenuated by hrHPV,
we utilized a system that resembles the natural infection with
hrHPV as closely as possible. Primary KCs stably maintaining the
hrHPV genome as episomes (hrHPVþKCs) display similar
growth properties as non-transfected KCs, and upon culture in
organotypic raft cultures, mimic HPV infection in vivo as docu-
mented by genome ampliﬁcation, late gene expression and virus
production during the differentiation-dependent life cycle of
HPV18–20.
The presence of HPV type 16 (HPV16) was clearly associated
with an impaired capacity to respond to IFN-g and to TNF-a, as
shown by the lower messenger RNA (mRNA) expression and
production of the IFN-g and/or TNF-a-induced pro-inﬂammatory
cytokines CCL2, RANTES (CCL5), interleukin (IL)-8 and the
chemokines CXCL9, 10 and 11 by KCs (Fig. 1a,b). Not only did
the presence of HPV16 impair the production of cytokines, also
the migration of peripheral blood mononuclear cells (PBMCs) to
supernatants of IFN-g and TNF-a-stimulated HPV16þKCs was
greatly impaired (Fig. 1c).
These data suggest that hrHPV, besides impairing the
innate immune response of KCs8, also suppresses the KCs
response to the adaptive immune signals provided by IFN-g and
TNF-a.
The hrHPV-mediated deregulated expression of STAT1
(refs 13–16) may explain the impaired cytokine expression by
hrHPV-positive KCs upon IFN-g stimulation, but not the
impaired response to TNF-a (IL-8) or to IFN-g and TNF-a
(RANTES). Previously, we showed that hrHPV hampers
phosphorylation of the NFkB subunit RelA (p65) upon
stimulation with the innate PRR ligand poly(I:C)8. As TNF-a
stimulation rapidly induces the phosphorylation of RelA17, we
tested whether hrHPV also hampers rapid TNF-a-induced RelA
phosphorylation by stimulating KCs and HPV16þKCs for 0, 5,
15 or 30min with TNF-a. Western blotting showed that RelA was
rapidly phosphorylated similarly in KCs and HPV16þKCs,
peaking after 15min of TNF-a stimulation (Fig. 1d), indicating
that the impairment of TNF-a-induced responses seen in
HPV16þKCs was not due to altered RelA phosphorylation
after short-term TNF-a stimulation. Activated NFkB translocates
to the nucleus where it is modiﬁed to regulate its DNA-binding
ability and transcriptional activity. Acetylation of the RelA
subunit at lysine 310 (K310) is crucial in this process17.
Strikingly, acetylated RelA K310 protein levels were lower in
the HPV16þKCs than in uninfected KCs, both in the absence of
stimulation and after short-term TNF-a stimulation (Fig. 1d).
The lowered basal RelA K310 acetylation state was veriﬁed in
three independent primary KC and two independent
HPV16þKC cultures (Fig. 1e), indicating that HPV hampers
the activity of NFkB already at steady-state levels. This was also
reﬂected in a lowered basal cytokine gene expression in
unstimulated HPV16þKCs (Fig. 1f).
HrHPV upregulates IFRD1 to impair RelA K310 acetylation.
Acetylation of RelA K310 can be regulated by the lysine acetyl
transferases (KAT) PCAF (KAT2B), CREBBP (KAT3A), p300
(KAT3B) and TIP60 (KAT5), as well as the HDACs 1 and 3
(ref. 17). Since our results imply that hrHPV has a mechanism
either to deacetylate or impair the acetylation of RelA, we
screened our validated microarray data12 for genes involved in
regulating RelA K310 acetylation. HrHPV did not signiﬁcantly
inﬂuence HDAC (HDAC1 to 11) or sirtuin (SIRT1 to 7)
expression (Fig. 2a). The only signiﬁcantly upregulated gene
was the lysine acetyl transferase CREBBP (KAT3A), conﬁrming
previous observations stating that HPV upregulates CREBBP to
enhance expression from episomal DNA21,22. However, as
CREBBP acetylates RelA its upregulation cannot explain the
observed lower levels of RelA K310 acetylation in hrHPV-infected
KCs under steady-state conditions. Interestingly, the microarray
data also showed the upregulation of IFRD1 (Fig. 2b),
which previously was shown to complex HDAC1 (ref. 23) and
HDAC3 to RelA causing its deacetylation at lysine 310 in the
mouse myoblast cell line C2C12 (ref. 24). We hypothesized that it
may fulﬁl a similar role in human KCs. Therefore, reverse
transcriptase (RT)–quantitative PCR (qPCR) and western
blotting was used to conﬁrm that IFRD1 gene expression
(Fig. 2c, left) and IFRD1 protein levels (Fig. 2d, left) were
elevated in two independent HPV16þKC cultures. Knockdown
of the polycistronic mRNA of HPV16 by a small interfering RNA
(siRNA) against HPV16 E2 in HPV16þKCs resulted in the
reduction of HPV16 E1, E2, E6 and E7 expression
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(Supplementary Fig. 1), IFRD1 mRNA (Fig. 2c, middle) and
IFRD1 protein levels (Fig. 2d, middle), indicating that the
augmented IFRD1 levels in hrHPVþKCs are the result of
the presence of hrHPV. Reciprocally, when undifferentiated
KCs were infected with native HPV16 virions, IFRD1 mRNA
(Fig. 2c, right) and IFRD1 protein (Fig. 2d, right) levels were
clearly enhanced after 2 days of infection. Furthermore,
immunohistochemistry of HPV-positive vulvar lesions revealed
the presence of IFRD1 in the nuclei of cells positive for HPV16 E2
(reﬂecting HPV-infected cells)25, but not in the nuclei of already
transformed KCs (identiﬁed through p16 staining25,26 or
undifferentiated (E2 and p16 negative) healthy tissue (Fig. 2e).
We then asked whether the hrHPV-induced increased levels of
IFRD1 affected RelA K310 acetylation also in human undiffer-
entiated KCs. Indeed, when lentivirus-delivered siRNA against
IFRD1 was used to lower IFRD1 protein expression, a
concomitant increase in the steady-state levels of acetylated RelA
K310 in HPV16þKCs was seen when compared with control
knockdown HPV16þKCs (Fig. 2f; Supplementary Fig. 2a).
Furthermore, a small increase in total RelA protein levels was
observed. The gain in acetylated RelA K310 translated into a
higher basal expression and secretion of cytokines in IFRD1 KD
cells (Fig. 2g–i), indicating that IFRD1 is involved in the
deregulation of steady-state inﬂammatory gene expression levels
0
200
400
400
1,600
CCL2 RANTES
0
500
1,000
1,500
IL8
0
10
20
30
40
CXCL9
0
4,000
8,000
12,000
16,000
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n
KC
HPV16+KC
*
**
***
**
**
***
**
**
**
***
***
**
***
***
Basal expression
0.00
0.25
0.50
0.75
1.00
1.25
CC
L2
CX
CL
9
IL
8
R
AN
TE
S
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n
o
ve
r 
co
n
tro
l K
Cs
**
**
**
0
500
1,000
1,500
2,000
2,500
IL8
0
200
400
600
800
1,000
CCL2
Co
nt
ro
l
IF
N
-γ
+
TN
F-
α
TN
F-
α
IF
N
-γ
Co
nt
ro
l
IF
N
-γ
+
TN
F-
α
TN
F-
α
IF
N
-γ
Co
nt
ro
l
IF
N
-γ
+
TN
F-
α
TN
F-
α
IF
N
-γ
Co
nt
ro
l
IF
N
-γ
+
TN
F-
α
TN
F-
α
IF
N
-γ
Co
nc
en
tra
tio
n 
(pg
 m
l–1
)
KC
HPV16+KC
# 
M
ig
ra
te
d 
PB
M
Cs
Migrated PBMCs
0
10,000
20,000
30,000
Co
nt
ro
l
IF
N
-γ
+
TN
F-
α
TN
F-
α
IF
N
-γ
**
***
**
**
**
0
10,000
20,000
30,000
40,000
CXCL9
**
0
4,000
8,000
12,000
RANTES
***
KC HPV16+KC
0 5 15 30 0 5 15 30
RelA
β-actin
RelA-Ac
RelA-P
Min. TNF-α
65
42
65
65
(kDa)
RelA-Ac
RelA
β-actin
KC HPV+KC
H
FK
H
VK
H
CK
H
FK
16
H
VK
16
65
65
42
(kDa)
Figure 1 | HPV16 impairs IFN-c and TNF-a-induced cytokine production and RelA K310 acetylation in KCs. (a) RT–qPCR of CCL2, RANTES, IL-8 and
CXCL9 expression by 24-h control, IFN-g- and/or TNF-a-stimulated undifferentiated KCs or HPV16þKCs. Gene expression was normalized using GAPDH
as the calibrator gene. Fold changes over control-stimulated undifferentiated KCs were calculated and depicted. (b) Enzyme-linked immunosorbent assay
for CCL2, RANTES, IL-8 and CXCL9 in cleared supernatants of 24-h control, IFN-g- and/or TNF-a-stimulated undifferentiated KCs or HPV16þKCs.
(c) PBMCs migration towards cleared supernatants of 24-h control, IFN-g- and/or TNF-a-stimulated KCs or HPV16þKCs. A representative example of
three different donors is shown. (d) RelA phosphorylation, acetylation and total levels in KCs and HPV16þKCs stimulated with TNF-a for 0, 5, 15 and
30min. (e) RelA acetylation and total levels at steady state in three human primary KC donor pools originating from human foreskin keratinocytes (HFKs),
human vaginal keratinocytes (HVKs) or human cervical keratinocytes (HCKs) and two HPV16þ genome-transfected primary KC pools of foreskin (HFK16)
or vaginal (HVK16) origin. (f) RT–qPCR of CCL2, RANTES, IL-8 and CXCL9 in HPV16þKCs and KCs. Gene expression was normalized using GAPDH as
the calibrator gene. Gene expression in HPV16þKCs was standardized over KCs. All data are representative for at least three independent experiments.
Error bars indicate s.d. P values were determined using Welch-corrected unpaired t-tests. *Po0.05, **Po0.01 and ***Po0.001.
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in HPV16þKCs. The dampening effect of IFRD1 on the NFkB-
regulated cytokine expression became even more apparent when
the KCs were stimulated with both IFN-g and TNF-a (Fig. 2h,i).
The cytokine levels produced after stimulation were much higher
in IFRD1 KD HPV16þKCs than in control KD HPV16þKCs.
Moreover, IFRD1 knockdown augmented the ability of HPV16þ
KCs to attract PBMCs (Fig. 2j). The main results were
recapitulated in HPV18-infected KCs (Supplementary Fig. 3),
suggesting that IFRD1 may form a general mechanism exploited
by any hrHPV type.
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As the effect of IFRD1 occurred directly at the level of RelA,
the inﬂuence of IFRD1 on the response of HPV16þKCs to
poly(I:C) stimulation, previously shown by us to be impaired in
hrHPV-infected KCs8, was also tested. Knockdown of IFRD1
resulted in an enhanced expression of CCL2, RANTES, IL-8 and
CXCL9 following PRR stimulation with poly(I:C) (Supplementary
Fig. 4).
Thus, hrHPV upregulates the expression of IFRD1 soon after
infection, thereby effectively decreasing the basal levels of
transcriptionally active RelA and as a consequence the levels of
pro-inﬂammatory cytokines induced via various innate and
adaptive immune-mediated NFkB stimulatory pathways.
EGFR signalling mediates the increased expression of IFRD1.
Growth factors, such as nerve growth factor, ﬁbroblast growth
factor or EGF, have previously been shown to induce the
expression of Tis family genes, which also includes IFRD1, in rat
neocortical astrocytes and chromafﬁn cell line PC12, mouse C243
and IEC-18, and mammary epithelial cells27. The hrHPV E5
protein is known to affect different aspects of EGFR signalling
and expression28. Veriﬁcation of EGFR expression in our model
showed that EGFR mRNA expression (Fig. 3a) and membrane-
bound protein expression (Fig. 3b) were higher in hrHPVþKCs
than in non-infected KCs. When we transfected complementary
DNA for E2 (as control), E5 or a mix of several other HPV
proteins, only E5 enhanced EGFR expression (Fig. 3c). To test
whether EGFR signalling had a similar effect on IFRD1 in human
primary KCs, the clinically used anti-EGFR antibody cetuximab
was employed to block EGFR signalling. Indeed, IFRD1
expression decreased in HPV16þKCs, but not in uninfected
KCs, when treated with cetuximab (Fig. 3d). IFRD1 protein levels
also decreased dose-dependently in both cetuximab-treated non-
infected KCs and HPV16þKCs (Fig. 3e). Notably, the isotype
control antibody rituximab (anti-CD20) had no effect (Fig. 3d,e).
Thus EGFR signalling does not only induce IFRD1 gene
expression but also stabilizes IFRD1 protein levels. Relative
density analysis revealed that in cetuximab-treated HPV16þKCs
the protein levels of IFRD1 decreased while concomitantly the
levels of RelA K310 acetylation increased in a dose-dependent
fashion. Total RelA levels were unaffected (Fig. 3f). These results
indicated that the HPV-induced expression of IFRD1 is mediated
via the EGFR signalling pathway, and implied that cetuximab
treatment may enhance the hrHPVþKCs pro-inﬂammatory
cytokine response to immune stimuli. Indeed, upon IFN-g and
TNF-a stimulation cetuximab-treated HPV16þKCs expressed
higher levels of indicated cytokine genes than rituximab-treated
cells (Fig. 3g), as well as higher levels of secreted cytokines
(Fig. 3h). In uninfected KCs, treatment with cetuximab decreased
the already low levels of IFRD1 protein, and although this led to
increased cytokine gene expression after IFN-g and TNF-a-
stimulation, no additional increase in the already high levels
of secreted cytokines was observed (Fig. 3g,h). The absence of
cytokine production in cetuximab-treated HPV16þKC and
uninfected KCs that were not stimulated with IFN-g and
TNF-a shows that binding of cetuximab to EGFR per se does
not result in the stimulation of cytokine production (Fig. 3g,h).
As EGFR signalling involves the downstream partners PI3K,
mTOR, MEK1, RAF and JNK, we selectively inhibited these
proteins using small-molecule inhibitors in HPV16þKCs
and observed that selective inhibition of mTOR (rapamycin),
MEK1 (PD98059) and RAF (GW5074), but not PI3K (LY94002)
or JNK (SP60025), resulted in decreased expression of
IFRD1 (Fig. 3i). Thus EGFR-mediated upregulation of IFRD1 is
fundamental to the impaired NFkB-induced cytokine response
of hrHPV-infected KCs to innate and adaptive immune
stimuli.
HDAC1/3 inhibition stimulates cytokine production. IFRD1-
mediated RelA deacetylation required the recruitment of HDAC1
and/or -3 to the RelA–IFRD1 complex in the mouse myoblast cell
line C2C12 (ref. 24). To test whether these HDACs played a
similar role in human hrHPVþKCs, the effect of HDAC
inhibition was tested in HPV16þKCs and non-infected KCs.
A dose titration of the HDAC1/3-speciﬁc inhibitor entinostat
(MS-275), and the prototypic pan-HDAC inhibitors trichostatin A,
sodium butyrate (NaBu) and the Food and Drug Administration-
approved vorinostat (suberoylanilide hydroxamic acid (SAHA))
was performed to study RelA K310 acetylation. All pan-HDAC
inhibitors increased RelA acetylation in KCs at the lowest
concentration used (Fig. 4a; Supplementary Fig. 2b), but at higher
doses cells suffered from toxic effects as observed by microscopy.
However, HPV16þKCs did survive entinostat treatment, and
clearly this HDAC1/3 inhibitor increased RelA K310 acetylation
in HPV16þKCs (Fig. 4a; Supplementary Fig. 2b). This indicated
that HDAC1 and/or -3 are indeed speciﬁcally involved in the
deacetylation of RelA in hrHPVþKCs. Entinostat treatment of
HPV16þKCs not only restored RelA K310 acetylation but also
released the suppressive effect of IFRD1 on cytokine production.
Treated HPV16þKCs displayed a higher basal expression for
three out of four tested cytokines when compared with their
untreated counterparts (Fig. 4b). Moreover, when stimulated with
IFN-g and TNF-a both KCs and HPV16þKCs displayed a
higher expression of CCL2, IL-8 and CXCL9, although the
expression of RANTES was abrogated (Fig. 4c). To conﬁrm the
Figure 2 | HrHPV upregulates IFRD1 to impair RelA K310 acetylation and basal cytokine expression. Microarray intensities for (a) all KATs, HDACs and
SIRTs, and (b) IFRD1 in four independent KCs and four independent hrHPVþKCs represented in a box plot. The box contains the 1st quartile up to the 3rd
quartile; the median is represented as a line; whiskers represent the values of the outer two quartiles. (c) IFRD1 mRNA expression of one representative
control primary KC culture and two HPV16þKC cultures (left panel), in HFK16 cells transfected with siControl or siHPV16 (middle panel) and in primary
KCs that are either mock infected or infected with native HPV16 virions (right panel), as measured by RT–qPCR. (d) IFRD1 protein expression in three
human primary keratinocyte (KC) donor pools originating from human foreskin keratinocytes (HFKs), human vaginal keratinocytes (HVKs) or human
cervical keratinocytes (HCKs) and two HPV16þ genome-transfected primary KC pools of foreskin (HFK16) or vaginal (HVK16) origin (left panel) in HFK16
cells transfected with siControl or siHPV16 (middle panel) and in primary KCs that are either mock infected or infected with native HPV16 virions (right
panel), as measured by western blot. (e) Immunohistochemical staining for IFRD1, HPV16 E2, p16 and negative antibody control of a vulvar intraepithelial
neoplasia (VIN) lesion, one representative donor of two shown. Counterstaining was done using haematoxylin. Scale bar, 500 mm. (f) IFRD1, RelA K310
acetylation and total RelA levels in 24-h non- or IFN-g- and TNF-a-stimulated control or IFRD1 knockdown (KD) HPV16þKCs. (g) RT–qPCR of CCL2,
RANTES, IL-8 and CXCL9 expression in steady-state control or IFRD1 KD HPV16þKCs. (h) RT–qPCR of CCL2, RANTES, IL-8 and CXCL9 expression in 24-h
non- or IFN-g- and/or TNF-a-stimulated control or IFRD1 KD HPV16þKCs. (i) Enzyme-linked immunosorbent assay for CCL2, RANTES, IL-8 and CXCL9 in
cleared supernatants of 24-h non- or IFN-g- and/or TNF-a-stimulated control or IFRD1 KD HPV16þKCs. (j) PBMCs migration towards cleared
supernatants of 24-h non- or IFN-g- and TNF-a-stimulated control or IFRD1 KD HPV16þKCs. A representative example of three different donors is shown.
These data are representative for at least three independent experiments. Error bars indicate s.d. P values were determined using Welch-corrected unpaired
t-tests. *Po0.05, **Po0.01 and ***Po0.001.
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involvement of RelA in this process, RelA was knocked down in
HPVþKCs (Fig. 4d), after which the cells were treated with
entinostat and stimulated with IFN-g and TNF-a. Indeed, RelA
acetylation and cytokine production was increased in the control
knockdown cells after stimulation with IFN-g and TNF-a when
treated with entinostat (Fig. 4d,e). However, when RelA was
knocked down in HPV16þKCs, the cytokine expression was
abrogated despite treatment with entinostat (Fig. 4e).
Co
nc
en
tra
tio
n 
(pg
 m
l–1
)
Co
nc
en
tra
tio
n 
(pg
 m
l–1
)
0
50
100
150
200
250
HPV16+KC
R
el
at
iv
e 
de
ns
ity
o
ve
r 
β-a
ct
in
 (%
)
0 0 0 Anti-EGFR
IFRD1 RelA-Ac RelA
Co
un
t
HPV16+KC
KC
Unstained
EGFR
EGFR
9
10
11
12
KC
hr
H
PV
+K
C
G
en
e 
ex
pr
es
sio
n 
(2l
og
) ***
IFRD1
0.0
0.5
1.0
1.5
0
Anti-EGFR Anti-CD20
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n KC
HPV16+KC**
*** ***
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n
0.00
0.25
0.50
0.75
1.00
1.25 IFRD1
Co
nt
ro
l
D
M
SO
PI
3K
m
TO
R
M
EK
1
R
AF JN
K
***
***
***
0
200
400
600
800
IL8
0
500
1,000
1,500
2,000
2,500
RANTES
0
500
1,000
1,500
CCL2
0
1,000
2,000
3,000
4,000
5,000
CXCL9
0
200
400
600
CCL2
0
2,000
4,000
6,000
RANTES
0.0
2.5
5.0
7.5
10.0
12.5
IL8
0
50,000
100,000
150,000
200,000
250,000
CXCL9
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n
Co
nt
ro
l
Co
nt
ro
l
Co
nt
ro
l
Co
nt
ro
l
KC
0
2,500
5,000
7,500
10,000
CCL2
0
500
1,000
1,500
2,000
2,500
RANTES
0
5
10
15
20
IL8
0
100,000
200,000
300,000
400,000
500,000
CXCL9
0
50
100
150
200
IL8
0
100
200
300
400
500
RANTES
0
100
200
300
400
CCL2
0
1,000
2,000
3,000
4,000
5,000
CXCL9
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n
Co
nt
ro
l
Co
nt
ro
l
Co
nt
ro
l
Co
nt
ro
l
HPV16+KC
Anti-CD20
Anti-EGFR
Anti-CD20
Anti-EGFR
IF
N
-γ
+
TN
F-
α
IF
N
-γ
+
TN
F-
α
IF
N
-γ
+
TN
F-
α
IF
N
-γ
+
TN
F-
α
 
 
IF
N
-γ
+
 T
N
F-
α
IF
N
-γ
+
TN
F-
α
IF
N
-γ
+
TN
F-
α
IF
N
-γ
+
TN
F-
α
*** ***
**
*
**
***
***
**
*
**
*
***
0.0
0.5
1.0
1.5
2.0
2.5
EGFR
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n
Co
nt
ro
l
E2 E5
E1
+E
2+
E6
+E
7
Anti-CD20Anti-EGFR
HPV16+KC HPV16+KCKC KCHP
V1
6+
KC
KC
IFRD1
β-actin
RelA
RelA-Ac
52
42
65
65
(kDa)
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7537
6 NATURE COMMUNICATIONS | 6:6537 | DOI: 10.1038/ncomms7537 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Previously, it was shown that HDAC inhibition abrogates
EGFR expression29,30, indicating that EGFR expression is
dependent on acetylation events. Indeed, entinostat treatment
dose-dependently abrogated EGFR expression in hrHPVþKCs,
but did not inﬂuence the expression in KCs (Fig. 4f).
Furthermore, entinostat treatment resulted in a reduced level of
IFRD1 protein in hrHPVþKCs (Fig. 4g), which made us wonder
whether IFRD1 could regulate EGFR expression. Therefore,
IFRD1 was knocked down in hrHPVþKCs and this resulted in
lower EGFR expression (Fig. 4h) and a lower level of membrane-
bound EGFR than control-treated hrHPVþKCs (Fig. 4i,j),
indicating that IFRD1 can control EGFR expression.
IFRD1 hampers the response of cancer cells to IFN-c and TNF-a.
To evaluate whether an increased expression of IFRD1 could also
play a role in HPV16-induced squamous cell carcinoma, we ana-
lysed the cell line Caski, as well as the two early-passage cervical
cancer cell lines, CSCC1 and CSCC7 (ref. 31). IFRD1 protein
expression differed between the cell lines (Fig. 5a), but was
increased in Caski and CSCC1 when compared with normal KCs.
RelA K310 acetylation was lower in all three cervical cancer cell
lines than in uninfected KCs (Fig. 5a; Supplementary Fig. 2c). For
the Caski and CSCC1 lines this may be explained by the presence
of upregulated IFRD1. However, the lack of RelA K310 acetylation
in the CSCC7 line indicates that, besides IFRD1 also other
mechanisms can alter the acetylation of RelA K310 in these
squamous cancer cells.
Because IFRD1 was upregulated in the Caski and CSCC1 cells,
we studied the effects of IFRD1 using these cell lines. IFRD1
knockdown in the CSCC1 cells did not alter basal cytokine
expression levels (Supplementary Fig. 5a), but IFRD1 knockdown
in the Caski cells resulted in a direct increase of the basal
expression levels of CCL2 and RANTES (Fig. 5b). Furthermore,
both cell lines showed increased cytokine gene levels upon IFN-g
and TNF-a stimulation when IFRD1 was knocked down as
compared with their control knockdown counterparts (Fig. 5c;
Supplementary Fig. 5b).
CSCC1 and Caski cells express EGFR (Fig. 5d) at a level that is
similar to that of uninfected KCs (Fig. 5e). However, the
downstream signalling pathway is known to be constitutively
higher in HPV-induced cancer cells32. As a consequence, the
treatment of Caski and CSCC1 cancer cells with the anti-EGFR
antibody cetuximab resulted in a higher production of IFN-g and
TNF-a-induced cytokines than when the cancer cells were treated
with the control anti-CD20 antibody rituximab (Fig. 5f;
Supplementary Fig. 5c). The enhanced response to IFN-g and
TNF-a was associated with a concomitant decrease in IFRD1
protein levels (Fig. 5g), but not mRNA expression (Fig. 5h), upon
EGFR blockade. Similarly, treatment of Caski and CSCC1 cancer
cells with entinostat resulted in a higher production of CCL2, IL-8
and CXCL9 by the cancer cells when stimulated with IFN-g and
TNF-a than dimethylsulphoxide carrier control-treated cells
(Fig. 5i; Supplementary Fig. 5d). Congruent with our earlier
observations, RANTES levels diminished after entinostat
treatment. These results suggest that IFRD1 may also play a
role in suppressing the response of cancer cells to immune stimuli
such as IFN-g and TNF-a.
Discussion
Using a unique in vitro model, we here show that hrHPV
infection leads to the upregulated expression of endogenous
IFRD1 to deregulate the K310 acetylation of NFkB/RelA. As a
result, hrHPV-infected KCs display an impaired production of
pro-inﬂammatory cytokines and chemokines, and a reduced
capacity to attract immune cells. The increased expression of
IFRD1 in hrHPVþKCs is mediated by EGFR signalling via
mTOR, RAF and/or MEK1. Knockdown of IFRD1 with siRNA or
indirectly via blockade of EGFR with the clinically used EGFR-
speciﬁc antibody cetuximab, resulted in decreased IFRD1 mRNA
and protein levels, increased NFkB/RelA K310 acetylation and
enhanced expression and production of pro-inﬂammatory
cytokines and chemokines by hrHPVþKCs. The use of
entinostat indicated that HDAC1 and/or -3 are involved in
lowering K310 acetylation of NFkB/RelA. These conclusions are
schematically represented in Fig. 5j.
EGFR activation on epithelial cells has been shown to result in
a decreased production of CCL2, RANTES and CXCL10 and
increased production of IL-8. Inhibition of EGFR signalling with
blocking antibodies or tyrosine kinase inhibitors can reverse the
effect on these cytokines, as well as result in an increased
epithelial immune inﬁltrate in vivo33–35. Interestingly, virus-
induced EGFR activation has been implicated as a novel
mechanism for respiratory viruses to suppress antiviral host
responses33. The exact underlying mechanism on EGFR-
mediated immune suppression remained unclear, albeit that
ERK1/2 signalling was shown to be involved in regulating
cytokine production and skin inﬂammation36. Using the EGFR-
blocking antibody cetuximab in the absence of an additional
EGFR stimulus such as the transforming growth factor-a,
we found similar effects on the cytokine production of
HPV16þKCs. In KCs, the expression of EGFR and IFRD1 are
tightly linked, as EGFR inhibition reduced the expression and
protein levels of IFRD1, via mTOR, RAF and/or MEK1, but not
PI3K or JNK. This ﬁts with the involvement of ERK1/2 in
regulating cytokine production36, since RAF and MEK1 are just
upstream of these kinases. On the basis of our data, the previously
observed EGFR activation-induced suppression of cytokine
production and immune cell inﬁltration of epithelia can be
explained by upregulation of IFRD1 and subsequent suppression
of NFkB signalling. Our data suggest that EGFR-driven
overexpression of IFRD1 may also play a role in deregulating
NFkB-signalling in HPV-induced tumour cells. Knockdown of
Figure 3 | Blocking EGFR signalling decreases IFRD1 levels and rescues cytokine production by hrHPVþKCs. (a) Microarray intensities for EGFR in
KCs (n¼4) and hrHPVþKCs (n¼4) represented in a box plot. (b) Histogram of EGFR surface protein expression on KCs and HPV16þKCs, as
determined by ﬂow cytometry. (c) RT–qPCR of EGFR expression in KCs transfected with complementary DNA for E2, E5, E1þ E2þ E6þ E7 or empty
control. (d) RT–qPCR of IFRD1 expression in KCs and HPV16þKCs treated for 72 h with 0, 0.1, 1 or 10mgml 1 anti-EGFR or anti-CD20. (e) IFRD1, RelA
K310 acetylation and total RelA levels in KCs and HPV16þKCs treated for 72 h with 0, 0.1, 1 or 10mgml 1 anti-EGFR or anti-CD20. (f) Quantiﬁed protein
levels of IFRD1, RelA K310 acetylation and RelA over b-actin in HPV16þKCs treated for 72 h with 0, 0.1, 1 or 10mgml 1 anti-EGFR (two-dimensional
western blot). The expression levels of the 0mgml 1-treated HPVþKCs were set as 100%. (g) RT–qPCR of CCL2, RANTES, IL-8 and CXCL9 expression in
24-h non- or IFN-g- and TNF-a-stimulated, anti-CD20- or anti-EGFR-treated HPV16þKCs (left) and KCs (right). (h) Enzyme-linked immunosorbent assay
for CCL2, RANTES, IL-8 and CXCL9 in cleared supernatants of 24-h non- or IFN-g- and TNF-a-stimulated, anti-CD20- or anti-EGFR-treated HPV16þKCs
(left) and KCs (right). (i) RT–qPCR of IFRD1 expression in HPV16þKCs treated with inhibitors of PI3K (LY94002, 25mM), mTOR (rapamycin, 50 nM),
MEK1 (PD98059, 50mM), RAF (GW5074, 20mM) and JNK (SP60025, 20mM). Gene expression was normalized using GAPDH as the calibrator gene. Fold
changes over control were calculated and depicted. These data are representative for at least three independent experiments, except for h that was
performed once. Error bars indicate s.d. P values were determined using Welch-corrected unpaired t-tests. *Po0.05, **Po0.01 and ***Po0.001.
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IFRD1 results in an increased production of pro-inﬂammatory
cytokines and chemokines by tumour cells when stimulated with
IFN-g and TNF-a. Furthermore, blocking of the EGFR by
cetuximab resulted in a decrease of IFRD1 protein levels, as well
as increased cytokine production. The HPV oncoproteins are also
known to directly intervene with NFkB signalling. Studies with
transfected or transformed cells—resembling protein expression
in tumour cells—show that E6 and/or E7 proteins inhibit basal
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and TNF-a-inducible NFkB activity37 by inﬂuencing NFkB
localization38,39 and activation40–43.
Studies in immunosuppressed patients and healthy individuals
show a key role for the adaptive immune response, in particular
that of a strong type-1 (IFN-g and TNF-a)-associated HPV early
antigen-speciﬁc T cells in the protection against progressive
disease5. This notion is sustained by the clinical responses of
patients treated with HPV-speciﬁc therapeutic vaccines5. Ample
reasons, therefore, for HPV to also develop strategies preventing
KCs to respond to these cytokines. Our data show that
HPV deploys multiple strategies to interfere with induced
RelA-associated NFkB signalling. HPV utilizes the cellular
deubiquitinase UCHL1 to interfere with TRAF3, TRAF6 and
NEMO function8, and here we show that HPV also upregulates
the expression of endogenous IFRD1 to deregulate the K310
acetylation of NFkB. Furthermore, the E7 protein of hrHPV has
been shown to bind HDAC1 and prevent acetylation of histones,
thereby suppressing TLR9 signaling44, but E7 can also displace
HDACs resulting in enhanced hypoxia-inducible factor-1a
transcriptional activity45. It is not unusual for viruses to target
NFkB activation46,47, and hampering RelA acetylation is a
common strategy. For instance, the N terminus of the orf
virus protein 002 inhibits acetylation of RelA by blocking
phosphorylation of RelA S276 and subsequent recruitment of
acetylases p300 and CBP48, and the A238L protein of the African
swine fever virus hampers RelA K310 acetylation by inhibiting
RelA–p300 interaction49. We here postulate that hrHPV does not
hamper KATs in acetylating RelA, but rather recruits a mediator
to enhance HDAC-mediated RelA deacetylation. Together with
our observation that HPV lowers basal cytokine expression in
resting KCs due to the presence of IFRD1, we suggest that
impairment of immune-driven RelA-associated NFkB-responsive
gene expression is crucial for the virus to persist. This viral
strategy has not been reported before, but as discussed above may
also be employed by respiratory viruses that activate EGFR33.
All together, our data indicate that HPV upregulates EGFR to
drive IFRD1 expression as a tool to decrease basal and adaptive-
immune system-driven cytokine expression. This may allow
hrHPV to evade the host’s immune response. It is highly likely
that this mechanism plays a role in other viral infections too and
even extends to tumours.
Methods
Ethics statement. The use of discarded human foreskin, cervical and vaginal KC
tissues to develop cell lines for these studies was approved by the institutional
review board at the Pennsylvania State University College of Medicine and by the
institutional review board at Pinnacle Health Hospitals. The Medical Ethical
Committee of the Leiden University Medical Center approved the human tissue
sections (healthy foreskin, healthy cervix and HPV16- or 18-positive cervical
neoplasias) used for staining. All sections and cell lines were derived from dis-
carded tissues and de-identiﬁed, therefore no informed consent was necessary.
Cell culture. Primary cultures of human epithelial KCs were established from
foreskin, vaginal, vulva and cervical tissues, as previously described3, and grown in
KC serum-free medium (Medium 154 supplemented with the HKGS kit,
Invitrogen, Breda, The Netherlands). KCs stably maintaining the full episomal
HPV genome following electroporation (HPV-positive KCs) were grown in
monolayer culture using E-medium in the presence of mitomycin C (Sigma-
Aldrich, Zwijndrecht, The Netherlands)-treated J2 3T3 feeder cells19,20 for two
passages and were then adapted to KC serum-free medium for one passage before
experimentation. J2 3T3 mouse ﬁbroblasts, Caski, CSCC1, CSCC7 and SiHa
cell lines were cultured in Iscove’s modiﬁed Dulbecco’s medium (IMDM)
supplemented with 8% fetal bovine serum, 2mM l-glutamine and 1% penicillin–
streptomycin (complete IMDM medium) (Gibco-BRL, Invitrogen).
HPV16 infection of non-infected KCs. Primary basal layer human foreskin KCs
were seeded at 75,000 cells per well in 24-well plates and allowed to attach for 48 h.
Cells received fresh medium (mock infected) or medium containing native HPV16
isolated from raft cultures at multiplicity of infection 100 for 24 h. Cells were
washed and harvested for either RT–qPCR or western blotting analysis.
IFRD1 and RelA knockdown in HPV-positive KCs. shRNAs were obtained from
the MISSION TRC-library of Sigma-Aldrich. The MISSION shRNA clones are
sequence-veriﬁed shRNA lentiviral plasmids (pLKO.1-puro) provided as frozen
bacterial glycerol stocks (Luria broth, carbenicillin at 100 mgml 1 and 10%
glycerol) in Escherichia coli for propagation and downstream puriﬁcation of the
shRNA clones. pLKO.1 contains the puromycin selection marker for transient
or stable transfection. The construct against IFRD1 (NM_001550) was
TRCN0000156194: 50-CCGGCAGTTCTGAAACAGTTTCTTTCTCGAGAAAGA
AACTGTTTCAGAACTGTTTTT-30, RelA (NM_021975) was TRCN0000014687:
50-CCGGCCTGAGGCTATAACTCGCCTACTCGAGTAGGCGAGTTATAGCCT
CAGGTTTTT-30 and the control was: SHC004 (MISSION TRC2-pLKO puro
TurboGFP shRNA control vector): 50-CCGGCGTGATCTTCACCGACAAGAT
CTCGAGATCTTGTCGGTGAAGATCACGTTTTT-30. HPV16-positive KCs at
B60% conﬂuence were transduced with lentivirus at multiplicity of infection 5–10
overnight, after which the medium was replaced. At least 72 h post transduction,
cells were stimulated as indicated and target gene expression was assayed by
RT–qPCR or western blotting.
HPV knockdown in HPV-positive KCs. Silencer Select siRNA against HPV16 E2
(50-AACACUACACCCAUAGUACAUtt-30) was designed using siRNA Target
Finder software (Ambion, Invitrogen). Blast search revealed that the designed E2
siRNA does not match with the known human transcriptome. E2 and negative
control #2 siRNA (sequence not provided by the manufacturer) were purchased
from Ambion. HPV16þKCs were transfected with 50 nM siRNA E2 or negative
control #2 using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s
instructions. Forty-eight hours post transfection, cells were harvested or stimulated
as indicated and target gene expression was assayed by RT–qPCR or western
blotting.
Transfection of HPV genes into non-infected KCs. Non-infected primary
KCs were seeded at 50,000 cells per well in 24-well plates and allowed to attach
overnight. Cells were transfected with 500 ng DNA using Lipofectamine
(Invitrogen), according to the manufacturer’s instructions. Cells were maintained
in E-medium. Seventy-two hours post transfection, cells were harvested and target
gene expression was assayed by RT–qPCR.
EGFR signalling blocking. Subconﬂuent cells were cultured in respective complete
growth medium in the presence of cetuximab (0.1, 1 or 10 mgml 1; Merck serono),
rituximab (0.1, 1 or 10mgml 1; Roche), rapamycin (50 nM; Calbiochem),
PD98059 (50 mM; Sigma-Aldrich), GW5074 (20 mM; Sigma-Aldrich), LY94002
(25 mM; Sigma-Aldrich) or SP60025 (20 mM; Sigma-Aldrich). Medium was
changed every 2–3 days. After at least 72 h, cells were stimulated as indicated and
target gene expression was assayed by RT–qPCR or western blotting.
Figure 4 | Entinostat treatment reveals involvement of HDAC1/3 in RelA deacetylation in HPV16þKCs. (a) RelA K310 acetylation and total RelA levels
in KCs and HPV16þKCs treated with decreasing doses of entinostat (40, 20, 10 and 2 mM), SAHA (10, 5 and 1 mM), TSA (5, 1 and 0.333 mM) or NaBu
(10, 5 and 1mM). RT–qPCR of CCL2, RANTES, IL-8 and CXCL9 expression in steady state (b) or 24-h non- or IFN-g- and TNF-a-stimulated (c) control or
entinostat (10 mM) pre-treated HPV16þKCs. (d) Total RelA levels and RelA K310 acetylation in non- or entinostat-treated control or RelA knockdown (KD)
HPV16þKCs. (e) RT–qPCR of CCL2, RANTES, IL-8 and CXCL9 expression in 24-h non- or IFN-g- and TNF-a-stimulated non- or entinostat-treated control or
RelA knockdown (KD) HPV16þKCs. (f) RT–qPCR of EGFR expression in KCs and HPV16þKCs treated with increasing doses of entinostat (0, 10 or
40mM). Gene expression was normalized using GAPDH as the calibrator gene. (g) IFRD1 in control or entinostat (10 mM) pre-treated HPV16þKCs.
(h) RT–qPCR of IFRD1 and EGFR expression in control or IFRD1 KD HPV16þKCs. Gene expression was normalized using GAPDH as the calibrator gene.
Histogram (i) and geomean (j) of EGFR expression on control or IFRD1 KD HPV16þKCs, as determined by ﬂow cytometry. s.e.m. of two independent
experiments. These data are representative for at least two independent experiments. Error bars indicate s.d. P values were determined using
Welch-corrected unpaired t-tests. *Po0.05, **Po0.01 and ***Po0.001.
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Figure 5 | Role of IFRD1 in hrHPVþ cervical cancer cells. (a) IFRD1, RelA acetylation and total RelA levels at steady state in three KC donors and three
HPV16-induced CxCa lines. (b) RT–qPCR of IFRD1, CCL2, RANTES, IL-8 and CXCL9 expression, and IFRD1 protein levels in steady-state control or IFRD1 KD
Caski cells. (c) RT–qPCR of CCL2, RANTES, IL-8 and CXCL9 expression in 24-h non- or IFN-g- and TNF-a-stimulated control or IFRD1 KD Caski cells.
(d) Histogram of EGFR expression on three HPV16-induced CxCa lines. (e) Geomean of EGFR expression on KCs and CxCa, as determined by ﬂow
cytometry. s.e.m. of two independent experiments. (f) RT–qPCR of CCL2, RANTES, IL-8 and CXCL9 expression in 24-h non- or IFN-g- and TNF-a-stimulated
anti-CD20- or anti-EGFR-treated Caski cells. (g) IFRD1 and RelA K310 acetylation status in Caski cells treated for 72 h with 0, 1 or 10mgml 1 anti-EGFR
(cetuximab) or anti-CD20 (rituximab). (h) RT–qPCR of IFRD1 expression in KCs and Caski cells treated for 72 h with 0, 0.1, 1 or 10mgml 1 anti-EGFR or
anti-CD20. (i) RT–qPCR of CCL2, RANTES, IL-8 and CXCL9 expression in 24-h non- or IFN-g- and TNF-a-stimulated control (dimethylsulphoxide (DMSO))
or entinostat-treated Caski cells. (j) Schematic representation of IFRD1-mediated RelA (de-)acetylation. (I) In KCs, RelA acetylation is positively
regulated by KATs, resulting in the production of pro-inﬂammatory cytokines. HDACs may suppress this process. (II) In HPVþKCs, elevated EGFR levels
can induce the expression of IFRD1, which can mediate RelA deacetylation by forming a bridge between RelA and HDAC1 and/or -3, hampering
pro-inﬂammatory gene expression. (III) Interfering with EGFR signalling (1 and 2) or HDAC function (3) may lower IFRD1 levels, restoring the RelA
acetylation balance, augmenting pro-inﬂammatory gene expression. Error bars indicate s.d. P values were determined using Welch-corrected unpaired
t-tests. *Po0.05, **Po0.01 and ***Po0.001.
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HDAC inhibition. Subconﬂuent cells were cultured in presence of a dilution series
of entinostat (MS-175; 40, 20, 10 and 2 mM; Selleckchem BioConnect), vorinostat
(SAHA; 10, 5 and 1 mM; Sigma-Aldrich), trichostatin A (5, 1 and 0.333 mM; Sigma-
Aldrich) or sodium butyrate (NaBu; 10, 5 and 1mM; Sigma-Aldrich) in the
respective complete growth medium overnight. Medium was changed for the
respective complete growth medium, cells were stimulated as indicated and target
gene expression was assayed by RT–qPCR or western blotting. Since treatment
with 10 mM entinostat showed a good increase in RelA K310 acetylation without
signs of toxicity, subsequent experiments were performed using this dose.
Migration assays. (HPV-positive) KCs were stimulated as indicated for 24 h.
Cleared (HPV-positive) KC supernatants were added to the lower compartment
of a transwell plate (Corning). The upper compartment was ﬁlled with PBMCs
isolated from buffy coats (Sanquin). PBMCs were allowed to migrate for 16 h,
after which the cells in the lower compartment were counted by ﬂow cytometry in
the presence of counting beads (Invitrogen), according to the manufacturer’s
instructions. Myeloid cells and lymphocytes were differentiated by their respective
size in the Forward Scatter (FSC)/Side Scatter (SSC) plot (data not shown).
RNA expression analyses and ELISA. The microarray data12 are accessible in the
Gene Expression Omnibus database (accession number GSE54181). Plots were
generated using the webtool R2: microarray analysis and visualization platform
(http://r2.amc.nl).
Total RNA was isolated using the NucleoSpin RNA II kit (Machery-Nagel,
Leiden, The Netherlands) according to the manufacturer’s instructions. Total RNA
(0.5–1.0 mg) was reverse transcribed using the SuperScript III First Strand synthesis
system from Invitrogen. TaqMan PCR was performed using the TaqMan Universal
PCR Master Mix and pre-designed, pre-optimized primers and probe mix for
CCL2, RANTES (CCL5), IL-8 (CXCL8), CXCL9 and GAPDH (Applied
Biosystems, Foster City, USA). Threshold cycle numbers (Ct) were determined
using the CFX PCR System (Bio-Rad, Veenendaal, The Netherlands), and the
relative quantities of complementary DNA per sample were calculated using the
DDCt method using GAPDH as the calibrator gene.
Enzyme-linked immunosorbent assays (ELISAs) for CCL2, RANTES, IL-8 and
CXCL9 were performed according to the manufacturer’s instruction (PeproTech,
London, UK).
Flow cytometry. Expression of EGFR on KCs was analysed by ﬂow cytometry
using phycoerythrin (PE)-coupled mouse-anti-human EGFR (1:20, BD Biosciences,
Breda, The Netherlands). Per live gate, 50,000 cells were recorded using the BD
FACS Calibur with Cellquest software (BD Bioscience) and data were analysed
using Flowjo (Treestar, Olten, Switzerland).
Western blot analysis. For western blotting, polypeptides were resolved by
SDS–polyacrylamide gel electrophoresis and transferred to a nitrocellulose
membrane (Bio-Rad). Immunodetection was achieved with anti-p65 (1:1,000,
sc-372, Santa Cruz), anti-phospho-p65 (Ser536; 1:1,000, #3033 Cell Signaling
Technology (CST)), anti-acetyl-p65 (Lys310; 1:1,000, #3045 CST), anti-IFRD1
(1:400, T2576 Sigma-Aldrich), b-actin (1:10,000, Sigma-Aldrich) primary
antibodies, and horseradish peroxidase-coupled anti-mouse (1:5,000; CST) and
horseradish peroxidase-coupled anti-rabbit (1:5,000, CST) secondary antibodies.
Chemoluminescence reagent (Bio-Rad) was used as a substrate and the signal was
scanned using the Chemidoc and accompanying software (Bio-Rad) to quantify the
intensity of the bands as a measure of the amount of protein of interest in the blot.
The relative amount was determined by calculating the ratio of each protein
over that of the density measured for the housekeeping protein b-actin. Images
have been cropped for presentation. Full-size images are presented in
Supplementary Fig. 6.
Immunohistochemistry. Four mm formalin-ﬁxed, parafﬁn-embedded tissue sec-
tions from two random vulvar intraepithelial neoplasia cases were deparafﬁnized
and rehydrated using graded concentrations of ethanol to distilled water.
Endogenous peroxidise activity was blocked with 0.03% H2O2/MeOH for 20min.
Antigen retrieval was performed in boiling EDTA buffer (pH 9.0) for 12min. After
2 h of cooling down to room temperature, slides were washed twice in distilled
water and twice in PBS. Subsequently, incubation was performed overnight at
room temperature with the primary IFRD1 antibody (T2576 Sigma-Aldrich; 1:500
in PBS containing 1% bovine serum albumin); p16 (CINTEC, diluted 1:5) and E2
(1:50) (provided by Dr F. Thierry). Second, sections were incubated with Bright-
Vision polyhorseradish peroxidase anti-mouse/rabbit/rat immunoglobulin-G
(Immunologic BV, Duiven, The Netherlands) for 30min at room temperature.
Washing between incubations was performed three times for 5min in PBS.
Immune complexes were visualized by applying a 0.05-M tris-HCl buffer (pH 7.6)
containing 0.05% of 3,30-diamino-benzidine-tetrahydrochloride and 0.0018% of
H2O2. After 10min, the reaction was stopped by rinsing with demineralized water.
Finally, the tissue sections were counterstained with Mayer’s haematoxylin before
addition of a coverslip.
Statistical analysis. Statistical analysis was performed using GraphPad InStat
version 3.00. P values were determined using Welch-corrected unpaired t-tests.
*Po0.05, **Po0.01 and ***Po0.001.
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